Sphingolipids : From Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina Obeid
van Echten-Deckert, Gerhild
Sphingolipids : From Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina Obeid - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (292 p.)
Open Access
Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain-which contains the largest amounts of sphingolipids in the body-and first description in 1884 by J.L.W. Thudichum, sphingolipids have been overlooked for almost a century, perhaps due to their complexity and enigmatic nature. When sphingolipidoses were discovered, a series of inherited diseases caused by enzyme mutations involved in sphingolipid degradation returned to the limelight. The essential breakthrough came decades later, in the 1990s, with the discovery that sphingolipids were not just structural elements of cellular membranes but intra- and extracellular signaling molecules. It turned out that their lipid backbones, including ceramide and sphingosine-1-phosphate, had selective physiological functions. Thus, sphingolipids emerged as essential players in several pathologies including cancer, diabetes, neurodegenerative disorders, and autoimmune diseases. The present volume reflects upon the unexpectedly eclectic functions of sphingolipids in health, disease, and therapy. This fascinating lipid class will continue to be the subject of up-and-coming future discoveries, especially with regard to new therapeutic strategies.
Creative Commons
English
books978-3-03943-958-4 9783039439577 9783039439584
10.3390/books978-3-03943-958-4 doi
Research & information: general
Biology, life sciences
S1P receptor inflammation S1P transporter spinster homolog 2 barrier dysfunction anxiety depression sphingolipids sphingomyelinase ceramidase Smpd1 acid sphingomyelinase forebrain depressive-like behavior anxiety-like behavior ceramide ceramides ceramidases neurodegenerative diseases infectious diseases sphingosine 1-phoshate sphingosine 1-phosphate receptor S1P1-5 sphingosine 1-phosphate metabolism sphingosine 1-phosphate antagonistst/inhibitors sphingosine 1-phosphate signaling stroke multiple sclerosis neurodegeneration fingolimod Sphingosine-1-phosphate obesity type 2 diabetes insulin resistance pancreatic β cell fate hypothalamus sphingosine-1-phosphate ischemia/reperfusion cardioprotection vasoconstriction coronary flow myocardial function myocardial infarct albumin type 1 diabetes beta-cells islets insulin cytokines S1P animal models cystic fibrosis autophagy myriocin Aspergillus fumigatus CLN3 disease Cln3Δex7/8 mice flupirtine allyl carbamate derivative apoptosis cancer gangliosides immunotherapy metastasis phenotype switching sphingosine 1-phosphate Sphingosine 1-phosphate (S1P) S1P-lyase (SGPL1) tau calcium histone acetylation hippocampus cortex astrocytes neurons sphingosine kinase G-protein-coupled receptors Gαq/11 n/a sphingosine kinase 1 SK1 microRNA transcription factor hypoxia long non-coding RNA
Sphingolipids : From Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina Obeid - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (292 p.)
Open Access
Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain-which contains the largest amounts of sphingolipids in the body-and first description in 1884 by J.L.W. Thudichum, sphingolipids have been overlooked for almost a century, perhaps due to their complexity and enigmatic nature. When sphingolipidoses were discovered, a series of inherited diseases caused by enzyme mutations involved in sphingolipid degradation returned to the limelight. The essential breakthrough came decades later, in the 1990s, with the discovery that sphingolipids were not just structural elements of cellular membranes but intra- and extracellular signaling molecules. It turned out that their lipid backbones, including ceramide and sphingosine-1-phosphate, had selective physiological functions. Thus, sphingolipids emerged as essential players in several pathologies including cancer, diabetes, neurodegenerative disorders, and autoimmune diseases. The present volume reflects upon the unexpectedly eclectic functions of sphingolipids in health, disease, and therapy. This fascinating lipid class will continue to be the subject of up-and-coming future discoveries, especially with regard to new therapeutic strategies.
Creative Commons
English
books978-3-03943-958-4 9783039439577 9783039439584
10.3390/books978-3-03943-958-4 doi
Research & information: general
Biology, life sciences
S1P receptor inflammation S1P transporter spinster homolog 2 barrier dysfunction anxiety depression sphingolipids sphingomyelinase ceramidase Smpd1 acid sphingomyelinase forebrain depressive-like behavior anxiety-like behavior ceramide ceramides ceramidases neurodegenerative diseases infectious diseases sphingosine 1-phoshate sphingosine 1-phosphate receptor S1P1-5 sphingosine 1-phosphate metabolism sphingosine 1-phosphate antagonistst/inhibitors sphingosine 1-phosphate signaling stroke multiple sclerosis neurodegeneration fingolimod Sphingosine-1-phosphate obesity type 2 diabetes insulin resistance pancreatic β cell fate hypothalamus sphingosine-1-phosphate ischemia/reperfusion cardioprotection vasoconstriction coronary flow myocardial function myocardial infarct albumin type 1 diabetes beta-cells islets insulin cytokines S1P animal models cystic fibrosis autophagy myriocin Aspergillus fumigatus CLN3 disease Cln3Δex7/8 mice flupirtine allyl carbamate derivative apoptosis cancer gangliosides immunotherapy metastasis phenotype switching sphingosine 1-phosphate Sphingosine 1-phosphate (S1P) S1P-lyase (SGPL1) tau calcium histone acetylation hippocampus cortex astrocytes neurons sphingosine kinase G-protein-coupled receptors Gαq/11 n/a sphingosine kinase 1 SK1 microRNA transcription factor hypoxia long non-coding RNA